Ambu A/S (AMBU-B) - Total Assets
Based on the latest financial reports, Ambu A/S (AMBU-B) holds total assets worth Dkr7.61 Billion DKK (≈ $1.19 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check AMBU-B cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Ambu A/S - Total Assets Trend (2002–2025)
This chart illustrates how Ambu A/S's total assets have evolved over time, based on quarterly financial data. Check Ambu A/S (AMBU-B) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Ambu A/S - Asset Composition Analysis
Current Asset Composition (September 2025)
Ambu A/S's total assets of Dkr7.61 Billion consist of 41.1% current assets and 58.9% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 11.3% |
| Accounts Receivable | Dkr907.00 Million | 11.8% |
| Inventory | Dkr1.27 Billion | 16.6% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr1.75 Billion | 22.8% |
| Goodwill | Dkr1.50 Billion | 19.5% |
Asset Composition Trend (2002–2025)
This chart illustrates how Ambu A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AMBU-B market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ambu A/S's current assets represent 41.1% of total assets in 2025, a decrease from 50.6% in 2002.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2025, up from 4.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 25.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 22.8% of total assets.
Ambu A/S Competitors by Total Assets
Key competitors of Ambu A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Truscreen Group Ltd
AU:TRU
|
Australia | AU$4.30 Million |
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
USA | $93.42 Million |
|
Guangdong Biolight Meditech Co Ltd
SHE:300246
|
China | CN¥2.46 Billion |
|
Rua Life Sciences PLC
LSE:RUA
|
UK | GBX9.12 Million |
|
Semler Scientific Inc
NASDAQ:SMLR
|
USA | $596.68 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥1.59 Billion |
|
Cardiex Ltd
AU:CDX
|
Australia | AU$16.99 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
Ambu A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.92 | 2.88 | 1.15 |
| Quick Ratio | 1.73 | 1.67 | 0.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr1.98 Billion | Dkr1.89 Billion | Dkr203.00 Million |
Ambu A/S - Advanced Valuation Insights
This section examines the relationship between Ambu A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.71 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 7.3% |
| Total Assets | Dkr7.67 Billion |
| Market Capitalization | $2.26 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Ambu A/S's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ambu A/S's assets grew by 7.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ambu A/S (2002–2025)
The table below shows the annual total assets of Ambu A/S from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | Dkr7.67 Billion ≈ $1.20 Billion |
+7.28% |
| 2024-09-30 | Dkr7.15 Billion ≈ $1.12 Billion |
+4.30% |
| 2023-09-30 | Dkr6.86 Billion ≈ $1.07 Billion |
-4.93% |
| 2022-09-30 | Dkr7.21 Billion ≈ $1.13 Billion |
+25.70% |
| 2021-09-30 | Dkr5.74 Billion ≈ $898.06 Million |
+16.52% |
| 2020-09-30 | Dkr4.93 Billion ≈ $770.71 Million |
+8.07% |
| 2019-09-30 | Dkr4.56 Billion ≈ $713.13 Million |
+7.65% |
| 2018-09-30 | Dkr4.23 Billion ≈ $662.44 Million |
+69.36% |
| 2017-09-30 | Dkr2.50 Billion ≈ $391.14 Million |
+5.66% |
| 2016-09-30 | Dkr2.37 Billion ≈ $370.18 Million |
+4.97% |
| 2015-09-30 | Dkr2.25 Billion ≈ $352.65 Million |
+10.11% |
| 2014-09-30 | Dkr2.05 Billion ≈ $320.27 Million |
+8.25% |
| 2013-09-30 | Dkr1.89 Billion ≈ $295.86 Million |
+95.86% |
| 2012-09-30 | Dkr965.51 Million ≈ $151.06 Million |
+8.59% |
| 2011-09-30 | Dkr889.16 Million ≈ $139.11 Million |
+1.52% |
| 2010-09-30 | Dkr875.87 Million ≈ $137.04 Million |
+12.05% |
| 2009-09-30 | Dkr781.66 Million ≈ $122.30 Million |
+6.75% |
| 2008-09-30 | Dkr732.22 Million ≈ $114.56 Million |
+7.56% |
| 2007-09-30 | Dkr680.77 Million ≈ $106.51 Million |
+0.45% |
| 2006-09-30 | Dkr677.74 Million ≈ $106.04 Million |
+3.00% |
| 2005-09-30 | Dkr658.01 Million ≈ $102.95 Million |
+11.32% |
| 2004-09-30 | Dkr591.11 Million ≈ $92.48 Million |
+6.31% |
| 2003-09-30 | Dkr556.04 Million ≈ $87.00 Million |
-1.27% |
| 2002-09-30 | Dkr563.20 Million ≈ $88.12 Million |
-- |
About Ambu A/S
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as… Read more